JP4508650B2 - アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物 - Google Patents

アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物 Download PDF

Info

Publication number
JP4508650B2
JP4508650B2 JP2003564054A JP2003564054A JP4508650B2 JP 4508650 B2 JP4508650 B2 JP 4508650B2 JP 2003564054 A JP2003564054 A JP 2003564054A JP 2003564054 A JP2003564054 A JP 2003564054A JP 4508650 B2 JP4508650 B2 JP 4508650B2
Authority
JP
Japan
Prior art keywords
group
alkyl
compound
hydroxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003564054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519922A5 (https=
JP2005519922A (ja
Inventor
ロバート・エイ・デインズ
ウィリアム・ヘンリー・ミラー
ニール・デイビッド・ピアソン
イズレイル・ペンドラク
マーク・アンドリュー・シーフェルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202025A external-priority patent/GB0202025D0/en
Priority claimed from GB0229819A external-priority patent/GB0229819D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005519922A publication Critical patent/JP2005519922A/ja
Publication of JP2005519922A5 publication Critical patent/JP2005519922A5/ja
Application granted granted Critical
Publication of JP4508650B2 publication Critical patent/JP4508650B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
JP2003564054A 2002-01-29 2003-01-27 アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物 Expired - Fee Related JP4508650B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202025A GB0202025D0 (en) 2002-01-29 2002-01-29 Compounds
GB0229819A GB0229819D0 (en) 2002-12-20 2002-12-20 Compounds
PCT/EP2003/000824 WO2003064431A2 (en) 2002-01-29 2003-01-27 Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
JP2005519922A JP2005519922A (ja) 2005-07-07
JP2005519922A5 JP2005519922A5 (https=) 2006-01-12
JP4508650B2 true JP4508650B2 (ja) 2010-07-21

Family

ID=27665356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564054A Expired - Fee Related JP4508650B2 (ja) 2002-01-29 2003-01-27 アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物

Country Status (5)

Country Link
US (1) US7109213B2 (https=)
EP (1) EP1470131A2 (https=)
JP (1) JP4508650B2 (https=)
AU (1) AU2003239302A1 (https=)
WO (1) WO2003064431A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803369B1 (en) 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) * 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
TW200406413A (en) * 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
US7232832B2 (en) * 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
WO2004050036A2 (en) * 2002-12-04 2004-06-17 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
AR042486A1 (es) * 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
JP2008505920A (ja) * 2004-07-08 2008-02-28 グラクソ グループ リミテッド 抗菌剤
WO2006017468A2 (en) 2004-08-02 2006-02-16 Glaxo Group Limited Antibacterial agents
EP1845995A4 (en) * 2005-01-25 2010-03-03 Glaxo Group Ltd ANTIBACTERIAL AGENTS
WO2006081182A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
JP2008528586A (ja) * 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528598A (ja) * 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
US7511035B2 (en) * 2005-01-25 2009-03-31 Glaxo Group Limited Antibacterial agents
JP5023054B2 (ja) 2005-03-31 2012-09-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としての二環式ピラゾール化合物
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
ES2340531T3 (es) * 2005-10-21 2010-06-04 Glaxo Group Limited Compuestos triciclos peri-condensados utiles como agentes antibacterianos.
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
ATE465163T1 (de) * 2005-12-22 2010-05-15 Glaxo Group Ltd Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
ATE536351T1 (de) 2006-01-26 2011-12-15 Actelion Pharmaceuticals Ltd Tetrahydropyran-antibiotika
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2007118130A2 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Antibacterial agents
EP2001887B1 (en) 2006-04-06 2010-09-15 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
GB0608263D0 (en) * 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
WO2008071964A1 (en) * 2006-12-15 2008-06-19 Astrazeneca Ab Naphthyridine bactericides
GB0705672D0 (en) * 2007-03-23 2007-05-02 Glaxo Group Ltd Compounds
GB0707708D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
AU2008240764C1 (en) * 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
GB0707706D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
EP2005995A1 (en) * 2007-06-22 2008-12-24 Glaxo Group Limited Heterocyclic compounds for the treatment of tuberculosis
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
EP2352734A1 (en) 2008-10-17 2011-08-10 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
US8318940B2 (en) 2009-01-15 2012-11-27 Glaxo Group Limited Naphthyridin-2 (1 H)-one compounds useful as antibacterials
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US10702521B2 (en) 2014-08-22 2020-07-07 Glaxosmithkline Intellectual Property Development Limited Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
TW201722965A (zh) 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1345872A (en) 1970-09-03 1974-02-06 Wyeth John & Brother Ltd Amino-and acylamino-pyridine and hydropyridine derivatives
GB1537867A (en) 1977-07-04 1979-01-04 Wyeth John & Brother Ltd Process for preparing 4-acylamino-piperidine derivatives
US4925877A (en) 1986-02-25 1990-05-15 Zaidanhojin Biseibutsu Kagaku Kenkyukai Physiologically active erbstatin analogue compounds and compositions
US4971996A (en) 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
ZA899436B (en) 1988-12-12 1990-08-29 Ciba Geigy Piperidine derivatives
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
EP0541486A1 (de) 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclische Konjugate
PT672041E (pt) 1993-10-01 2002-04-29 Novartis Ag Derivados da piridina farmacologicamente activos e processos para a sua preparacao
JPH07179407A (ja) 1993-11-12 1995-07-18 Green Cross Corp:The 新規縮合環系化合物またはその塩、およびその医薬用途
PL181893B1 (pl) 1994-11-14 2001-10-31 Warner Lambert Co Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL
ES2149468T3 (es) 1995-04-26 2000-11-01 Kyowa Hakko Kogyo Kk Derivados de radicicol.
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6077857A (en) 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
US5707990A (en) 1996-01-30 1998-01-13 Ortho Pharmaceutical Corporation 2-substituted amino and thio alkyl benzoxazine antimicrobial agents
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2318842A1 (en) 1998-01-26 1999-07-29 Julie Dorothy Warrack Quinoline derivatives as antibacterials
GB9822440D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9822450D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
JP2002535323A (ja) * 1999-01-20 2002-10-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー プロテインキナーゼ阻害剤としてのピペリジニルキノリン
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917406D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
US6403610B1 (en) 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6803369B1 (en) 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2002024684A1 (en) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0031086D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
FR2822154B1 (fr) 2001-03-13 2005-10-21 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
FR2822971A1 (fr) * 2001-04-03 2002-10-04 St Microelectronics Sa Systeme et procede de controle d'acces a des donnees protegees stockees dans une memoire
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030203917A1 (en) 2001-07-25 2003-10-30 Smithkline Beecham Corporation And Smithkline Beecham P.L.C. Compounds and methods for the treatment of neoplastic disease
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
EP1551829B1 (de) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
WO2004050036A2 (en) 2002-12-04 2004-06-17 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
US6903214B1 (en) * 2003-12-11 2005-06-07 Eastman Kodak Company Synthesis of bis(azinyl)amine-BF2 complex

Also Published As

Publication number Publication date
US20050085494A1 (en) 2005-04-21
EP1470131A2 (en) 2004-10-27
US7109213B2 (en) 2006-09-19
WO2003064431A3 (en) 2003-12-18
AU2003239302A1 (en) 2003-09-02
JP2005519922A (ja) 2005-07-07
WO2003064431A2 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
JP4508650B2 (ja) アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物
JP4445753B2 (ja) アミノピペリジン誘導体
JP4522262B2 (ja) 化合物
US7498326B2 (en) Compounds
ES2278778T3 (es) Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
JP4472928B2 (ja) 4位がピペリジン含有部分によって置換されたキノリンおよびその窒素化誘導体および抗菌薬としてのその使用
US7186730B2 (en) Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials
JP4463565B2 (ja) 抗菌剤として用いるための窒素含有二環式複素環
JP4515260B2 (ja) アミノシクロヘキセンキノリンおよび抗菌活性を有するそのアザアイソステリック類似体
EP1343780B1 (en) Piperazine derivatives for treatment of bacterial infections
JP2003502419A (ja) 抗菌剤としてのキノリン誘導体
JP2005504747A (ja) 薬物
ZA200300589B (en) Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091030

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100413

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100427

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130514

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees